



# KABRADRUGSLIMITED

CIN-L02423MP1989PLC005438

To  
listing Department,  
BSE Limited,  
P J Tower, Dalal Street  
Mumbai-400001

August 14, 2021

Dear Sir/Madam,

**Subject: Unaudited Financial Result for quarter ending 30th June, 2020 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015**

In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith unaudited financial result for quarter ended 30th June, 2021.

Kindly take the same on your record and oblige.

Thanking You,

For Kabra Drugs Limited

Authorized / Director



REGD OFFC: SHOP NO. 270, SHASTRI MARKET, INDORE M.P.

PHONE NO 0731-4247626

Email – [kabradrugs@gmail.com](mailto:kabradrugs@gmail.com), website- [www.kabradrugs.com](http://www.kabradrugs.com)

**KABRA DRUGS LTD.**

CIN:- L02423MP1989PLC005438

Regd. Office: Shop No. 270, Shastri Market, Indore - 452001

Email:- kabradrugs@gmail.com

**Statement of Unaudited Financial Results for the Quarter Ended June 30, 2021**

(Rs. In lacs)

Sl no.	Particulars	Quarter Ended 30 June 2021	Quarter Ended 31st March 2021	Quarter Ended 30 June 2020	Year Ended 31 Mar 2021
	(Refer Notes Below)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
<b>1</b>	<b>REVENUE FROM OPERATIONS</b>				
(a)	Income from Operations	-	-	-	-
(b)	Other Income	-	-	-	-
	<b>Total Income</b>	-	-	-	-
<b>2</b>	<b>EXPENSES</b>				
(a)	Cost of material consumed	-	-	-	-
(b)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	-	-	-
(c)	Employee benefit expense	1.50	4.80	-	4.80
(d)	Finance Costs	-	-	-	-
(e)	Depreciation and Amortization Expense	-	3.12	-	3.12
(f)	Other expenses	4.66	5.96	3.71	10.08
	<b>Total Expenses</b>	<b>6.16</b>	<b>13.88</b>	<b>3.71</b>	<b>18.00</b>
<b>3</b>	<b>Profit Before Exceptional items and tax</b>	<b>(6.16)</b>	<b>(13.88)</b>	<b>(3.71)</b>	<b>(18.00)</b>
4	Exceptional Items	-	-	-	-
<b>5</b>	<b>Profit / (Loss) before tax</b>	<b>(6.16)</b>	<b>(13.88)</b>	<b>(3.71)</b>	<b>(18.00)</b>
6	Tax Expense	-	-	-	-
<b>7</b>	<b>Net Profit for the period</b>	<b>(6.16)</b>	<b>(13.88)</b>	<b>(3.71)</b>	<b>(18.00)</b>
8	Other comprehensive income	-	-	-	-
<b>9</b>	<b>Total comprehensive income (9+10)</b>	<b>(6.16)</b>	<b>(13.88)</b>	<b>(3.71)</b>	<b>(18.00)</b>
10	Paid-up equity share capital (Face Value of Rs.10/- each)	<b>438.86</b>	<b>438.86</b>	<b>438.86</b>	<b>438.86</b>
11	Other Equity				(459.63)
<b>12</b>	<b>Earnings Per Share (of Rs. 10/- each):</b>				
(a)	Basic	(0.14)	(0.32)	(0.08)	(0.41)
(b)	Diluted	(0.14)	(0.32)	(0.08)	(0.41)

**Notes:**

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 14, 2021. The Statutory Auditors have carried out a limited review of the above financial result.
- Company has only one segment and hence no separate segment result has been given.
- The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Place : Indore

Date : 14th August, 2021



By order of the Board

  
Director



# RISHI SEKHRI AND ASSOCIATES CHARTERED ACCOUNTANTS

GROUND FLOOR, BANDRA ARCADE BUILDING, OPP. RAILWAY STATION, BANDRA (WEST), MUMBAI - 400 050.  
Tel.: 9820501848, 26419136, Email : rishisekhri@gmail.com

## Limited Review Report

To  
The Board of Directors of  
**KABRA DRUGS LTD.**  
Indore

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **KABRA DRUGS LTD.** ("the Company"), having registered office at Shop No. 270, Shastri Market, Indore - 45200 MP, for the Quarter ended June 30<sup>th</sup>, 2021 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulation") as amended, read with Circular No. CIR/CFD/CMD1/80/2019 dated July 19<sup>th</sup>, 2019 ("the Circular").

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR, RISHI SEKHRI AND ASSOCIATES,  
Chartered Accountants  
FRN: 128216W

CA RISHI SEKHRI  
PARTNER  
MEMBERSHIP NO. 126656

PLACE: MUMBAI  
DATE: 14.08.2020  
UDIN: 21126656AADEY7797

